Advertisement
Dr. Robert C. Moellering, Jr., M.D., will serve as Chairman of theClinical Advisory Board. From 1999 to 2005, Dr. Moellering was the Herrman L.Blumgart Professor of Medicine at Harvard Medical School and Chairman of theDepartment of Medicine at Beth Israel Deaconess Medical Center, Boston. He nowholds the Shields Warren-Mallinckrodt Chair of Medical Research at HarvardMedical School, and was the founder and served as the CEO of the HarvardMedical Faculty Physicians at Beth Israel Deaconess Medical Center until 2004.
Advertisement
Other individuals named to the Advisory Board include:
-- Helen W. Boucher, M.D., Assistant Professor of Medicine, TuftsUniversity School of Medicine, Director of the Infectious Diseases FellowshipProgram, and Staff Physician in the Division of Geographic Medicine andInfectious Diseases at Tufts Medical Center, Boston;
-- Henry F. Chambers, M.D., Chief Professor of Medicine in the Division ofInfectious Diseases at San Francisco General Hospital, and the Director of theUniversity of California, San Francisco Infectious Diseases FellowshipTraining Program;
-- Barbara E. Murray, M.D., Director of the Division of InfectiousDiseases at the University of Texas-Houston Medical School, and Co-Director ofthe UTHSC-H Center for the Study of Emerging and Re-Emerging Pathogens;
-- Leon G. Smith, M.D., Professor of Medicine and Preventive Medicine /Community Health at the University of Medicine and Dentistry of New Jersey,Chair of the Residency Program in Internal Medicine at Seton Hall UniversitySchool of Graduate Medical Education, and the Director of Medicine and Chiefof Infectious Disease at St. Michael's Medical Center;
-- Richard P. Wenzel, M.D., M.Sc., Professor and Chairman of theDepartment of Internal Medicine, Senior Associate Dean for Clinical Affairs,and President of MCV Physicians at the Medical College of Virginia/VirginiaCommonwealth University in Richmond, Virginia.
"This world-class Advisory Board was attracted to the Rib-X mission ofdiscovering and developing new therapies for life-threatening, resistantbacterial infections, and we are proud to have them as colleagues and advisorsat this important time in our growth," said Susan Froshauer, Ph.D, Presidentand CEO of Rib-X. "The formation of the Clinical Advisory Board is indicativeof our evolution as a Company and we look forward to working with these boardmembers to advance our clinical programs."
About Rib-X Pharmaceuticals, Inc.
Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drugdiscovery and development company focused on the structure-based design of newclasses of antibiotics. The Company's underlying drug discovery enginecapitalizes on its proprietary high-resolution crystal structure of theribosome, which performs an essential role in protein synthesis. Many known,commercially valuable antibiotics exert their effects by binding to thebacterial ribosome. The Company's integrated research strategy, which combinesstate-of-the-art, proprietary computational analysis, X-ray crystallography,medicinal chemistry, microbiology and biochemistry, allows it to rapidlysynthesize new agents designed to avoid typical antibiotic resistancemechanisms. Rib-X's iterative intelligent engine has yielded severaldistinctive new antibiotics that can be used for the treatment of eithercommunity- or hospital-acquired infections. Radezolid (RX-1741), anoxazolidinone, is an oral/IV ag
